Security record · archived quarter
PHAT
Phathom Pharmaceuticals, Inc. · Healthcare · Biotechnology
6Tracked holders
—Δ holders
1.55MShares held
$15.95MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 70 | +3 | 31.41M | $340.87M | +8 | −5 |
| Q1 2026 | 70 | +3 | 28.31M | $314.61M | +9 | −6 |
| Q4 2025 | 67 | +2 | 22.91M | $380.11M | +2 | — |
| Q3 2025 | 13 | +2 | 15.27M | $179.73M | +2 | — |
| Q2 2025 | 8 | -4 | 10.36M | $99.34M | — | −4 |
| Q1 2025 | 9 | 0 | 3.37M | $21.12M | — | — |
| Q4 2024 | 9 | 0 | 2.95M | $23.99M | +2 | −2 |
| Q3 2024 | 8 | +2 | 2.05M | $37.04M | +3 | −1 |
| Q2 2024 | 6 | — | 1.55M | $15.95M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 806.05K | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 806.05K | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Two Sigma Investments ✦ | 303.43K | — | $3.13M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 226.64K | — | $2.33M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 226.64K | — | $2.33M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 226.64K | — | $2.33M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 226.64K | — | $2.33M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Marshall Wace ✦ | 112.69K | — | $1.16M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 78.82K | — | $811,805 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 78.82K | — | $811,805 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 20.57K | — | $212,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 173 holders, 68.60M shares, $741.84M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API